RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection.
PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males
OUTLINE: This is a multicenter study.
Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine intramuscularly on day 1 and in weeks 8 and 24.
Blood and tissue samples may be collected periodically for laboratory studies.
After completion of study treatment, patients are followed up for 2 years.
Anal Cancer Nonneoplastic Condition Penile Cancer Precancerous Condition human papilloma virus infection HIV infection Vaccines
For males ages 13 years to 26 years
PRIOR CONCURRENT THERAPY:
© 2017 The Regents of the University of California